Ilorasertib

DB11694InvestigationalSmall molecule

Ilorasertib has been used in trials studying the treatment of Myelodysplasia, Solid Neoplasm, Advanced Cancers, Advanced Solid Tumors, and Acute Myelogenous Leukemia, among others.

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor
Curator reviewed
Formula / weight: C₂₅H₂₁FN₆O₂S · 488.54 g/mol (avg)
Code names: A-968660.0 · ABBOTT-968660 · ABT-348

Resolves to

Compound

UNII6L5D03D975CAS1227939-82-3ChEMBLCHEMBL1980297PubChem46207586

Structure

InChIKeyWPHKIQPVPYJNAX-UHFFFAOYSA-NSMILESNC1=C2C(SC=C2C2=CC=C(NC(=O)NC3=CC(F)=CC=C3)C=C2)=C(C=N1)C1=CN(CCO)N=C1

Targets

Q96GD4AURKBO14965AURKAQ9UQB9AURKC

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ilorasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account